Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing

Brandolini, Micaela and Cattelan, Anna Maria and Orani, Anna and Sighinolfi, Laura and Andreoni, Massimo and Nardini, G. and Sotgiu, Giovanni and Maserati, Renato (2008) Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing. Journal of the International AIDS Society, Vol. 11 (Suppl. 1), P56. ISSN 1758-2652. Article.

Preview

Full text disponibile come PDF Richiede visualizzatore di PDF come GSview, Xpdf o Adobe Acrobat Reader
132Kb

DOI: 10.1186/1758-2652-11-S1-P56

Abstract

We are conducting a multicenter, randomized, controlled, prospective, open trial to evaluate both the efficacy and toxicity of nevirapine (NVP) (given twice [BID] or once daily [QD]) in virologically-suppressed patients on a PIbased HAART. NVP BID dosing is maintained for 2 months after the switch in both groups.

Item Type:	Article
ID Code:	1136
Status:	Published
Refereed:	Yes
Uncontrolled Keywords:	Highly active antiretroviral therapy (HAART), nevirapine (NVP), HIV-RNA and plasma viral load (pVL)
Subjects:	Area 06 - Scienze mediche > MED/42 Igiene generale e applicata
Divisions:	001 Università di Sassari > 03 Istituti > Igiene e medicina preventiva
Publisher:	BioMed Central
ISSN:	1758-2652
Additional Information:	Poster presentato nel "Ninth International Congress on Drug Therapy in HIV infection", Glasgow, UK, 9-13 novembre 2008.
Deposited On:	18 Aug 2009 10:04

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page